AU2003259971B2 - Compositions and methods for treating skin conditions - Google Patents
Compositions and methods for treating skin conditions Download PDFInfo
- Publication number
- AU2003259971B2 AU2003259971B2 AU2003259971A AU2003259971A AU2003259971B2 AU 2003259971 B2 AU2003259971 B2 AU 2003259971B2 AU 2003259971 A AU2003259971 A AU 2003259971A AU 2003259971 A AU2003259971 A AU 2003259971A AU 2003259971 B2 AU2003259971 B2 AU 2003259971B2
- Authority
- AU
- Australia
- Prior art keywords
- calcium
- glycerophosphate
- skin
- group
- ionic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims description 37
- 238000000034 method Methods 0.000 title claims description 29
- 239000011575 calcium Substances 0.000 claims description 67
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 65
- 229960005069 calcium Drugs 0.000 claims description 65
- 229910052791 calcium Inorganic materials 0.000 claims description 65
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 claims description 33
- 235000019299 calcium glycerylphosphate Nutrition 0.000 claims description 32
- 239000001736 Calcium glycerylphosphate Substances 0.000 claims description 31
- 229940095618 calcium glycerophosphate Drugs 0.000 claims description 31
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 241000124008 Mammalia Species 0.000 claims description 14
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 13
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 13
- 239000006172 buffering agent Substances 0.000 claims description 11
- 125000003128 glycerophosphate group Chemical group 0.000 claims description 11
- 206010013786 Dry skin Diseases 0.000 claims description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- 208000027418 Wounds and injury Diseases 0.000 claims description 7
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 6
- 239000001110 calcium chloride Substances 0.000 claims description 6
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 6
- 239000000344 soap Substances 0.000 claims description 6
- 206010042496 Sunburn Diseases 0.000 claims description 5
- 230000037336 dry skin Effects 0.000 claims description 5
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 4
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 4
- 239000001639 calcium acetate Substances 0.000 claims description 4
- 235000011092 calcium acetate Nutrition 0.000 claims description 4
- 229960005147 calcium acetate Drugs 0.000 claims description 4
- 239000011692 calcium ascorbate Substances 0.000 claims description 4
- 235000010376 calcium ascorbate Nutrition 0.000 claims description 4
- 229940047036 calcium ascorbate Drugs 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 4
- 239000001354 calcium citrate Substances 0.000 claims description 4
- 229960004256 calcium citrate Drugs 0.000 claims description 4
- 239000004227 calcium gluconate Substances 0.000 claims description 4
- 235000013927 calcium gluconate Nutrition 0.000 claims description 4
- 229960004494 calcium gluconate Drugs 0.000 claims description 4
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 4
- 239000001527 calcium lactate Substances 0.000 claims description 4
- 235000011086 calcium lactate Nutrition 0.000 claims description 4
- 229960002401 calcium lactate Drugs 0.000 claims description 4
- 229960002079 calcium pantothenate Drugs 0.000 claims description 4
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims description 4
- HDRTWMBOUSPQON-ODZAUARKSA-L calcium;(z)-but-2-enedioate Chemical compound [Ca+2].[O-]C(=O)\C=C/C([O-])=O HDRTWMBOUSPQON-ODZAUARKSA-L 0.000 claims description 4
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 230000008439 repair process Effects 0.000 claims description 4
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- 150000002315 glycerophosphates Chemical class 0.000 claims description 3
- 230000035876 healing Effects 0.000 claims description 3
- 230000007794 irritation Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000002453 shampoo Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 235000001130 magnesium glycerophosphate Nutrition 0.000 claims description 2
- CBEYZWBXIPZYNH-UHFFFAOYSA-J 1,5-dihydroxypentan-3-yl phosphate;2,3-dihydroxypropyl phosphate;iron(2+) Chemical compound [Fe+2].[Fe+2].OCC(O)COP([O-])([O-])=O.OCCC(CCO)OP([O-])([O-])=O CBEYZWBXIPZYNH-UHFFFAOYSA-J 0.000 claims 1
- PNNHLULHRSZWPG-UHFFFAOYSA-J 1,5-dihydroxypentan-3-yl phosphate;2,3-dihydroxypropyl phosphate;manganese(2+) Chemical compound [Mn+2].[Mn+2].OCC(O)COP([O-])([O-])=O.OCCC(CCO)OP([O-])([O-])=O PNNHLULHRSZWPG-UHFFFAOYSA-J 0.000 claims 1
- YZDDKALBXAGVHK-VMJVVOMYSA-N OCC(O)COP(O)(O)=O.COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)c2c1.COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)c2c1 Chemical compound OCC(O)COP(O)(O)=O.COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)c2c1.COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)c2c1 YZDDKALBXAGVHK-VMJVVOMYSA-N 0.000 claims 1
- 206010040880 Skin irritation Diseases 0.000 claims 1
- JZJVSRKZXGLAMI-UHFFFAOYSA-L dilithium;2,3-dihydroxypropyl phosphate Chemical compound [Li+].[Li+].OCC(O)COP([O-])([O-])=O JZJVSRKZXGLAMI-UHFFFAOYSA-L 0.000 claims 1
- CHFUHGDBYUITQJ-UHFFFAOYSA-L dipotassium;2,3-dihydroxypropyl phosphate Chemical compound [K+].[K+].OCC(O)COP([O-])([O-])=O CHFUHGDBYUITQJ-UHFFFAOYSA-L 0.000 claims 1
- 239000011742 magnesium glycerophosphate Substances 0.000 claims 1
- BHJKUVVFSKEBEX-UHFFFAOYSA-L magnesium;2,3-dihydroxypropyl phosphate Chemical compound [Mg+2].OCC(O)COP([O-])([O-])=O BHJKUVVFSKEBEX-UHFFFAOYSA-L 0.000 claims 1
- 239000011584 manganese glycerophosphate Substances 0.000 claims 1
- 235000018348 manganese glycerophosphate Nutrition 0.000 claims 1
- 239000011600 potassium glycerophosphate Substances 0.000 claims 1
- 235000000491 potassium glycerophosphate Nutrition 0.000 claims 1
- 230000036556 skin irritation Effects 0.000 claims 1
- 231100000475 skin irritation Toxicity 0.000 claims 1
- 229960002901 sodium glycerophosphate Drugs 0.000 claims 1
- REULQIKBNNDNDX-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl hydrogen phosphate Chemical compound [Na+].OCC(O)COP(O)([O-])=O REULQIKBNNDNDX-UHFFFAOYSA-M 0.000 claims 1
- XLMCDAMBOROREP-UHFFFAOYSA-N zinc;3-phosphonooxypropane-1,2-diolate Chemical compound [Zn+2].OP(O)(=O)OCC([O-])C[O-] XLMCDAMBOROREP-UHFFFAOYSA-N 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 57
- 210000002510 keratinocyte Anatomy 0.000 description 13
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 12
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 229940106189 ceramide Drugs 0.000 description 12
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 12
- 230000004069 differentiation Effects 0.000 description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 210000000438 stratum basale Anatomy 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 5
- 210000004927 skin cell Anatomy 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229930002330 retinoic acid Natural products 0.000 description 4
- 229960001727 tretinoin Drugs 0.000 description 4
- 206010034972 Photosensitivity reaction Diseases 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000037311 normal skin Effects 0.000 description 3
- 230000036211 photosensitivity Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- -1 retinoid compounds Chemical class 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010048222 Xerosis Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 244000005714 skin microbiome Species 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000000437 stratum spinosum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- MQWCQFCZUNBTCM-UHFFFAOYSA-N 2-tert-butyl-6-(3-tert-butyl-2-hydroxy-5-methylphenyl)sulfanyl-4-methylphenol Chemical compound CC(C)(C)C1=CC(C)=CC(SC=2C(=C(C=C(C)C=2)C(C)(C)C)O)=C1O MQWCQFCZUNBTCM-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006797 Burns first degree Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100034866 Kallikrein-6 Human genes 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- YLCXGBZIZBEVPZ-UHFFFAOYSA-N Medazepam Chemical compound C12=CC(Cl)=CC=C2N(C)CCN=C1C1=CC=CC=C1 YLCXGBZIZBEVPZ-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Natural products C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 1
- 230000037338 UVA radiation Effects 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- UUGSWUCPQUGTJQ-UHFFFAOYSA-L calcium 3-hydroxy-2-phosphooxypropanoate Chemical compound P(=O)(=O)OC(C(=O)[O-])CO.[Ca+2].P(=O)(=O)OC(C(=O)[O-])CO UUGSWUCPQUGTJQ-UHFFFAOYSA-L 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- IWIRHXNCFWGFJE-UHFFFAOYSA-L calcium;2,3-dihydroxypropyl phosphate Chemical compound [Ca+2].OCC(O)COP([O-])([O-])=O IWIRHXNCFWGFJE-UHFFFAOYSA-L 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940022769 d- lactic acid Drugs 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40507802P | 2002-08-21 | 2002-08-21 | |
| US60/405,078 | 2002-08-21 | ||
| PCT/US2003/026194 WO2004017901A2 (en) | 2002-08-21 | 2003-08-20 | Compositions and methods for treating skin conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003259971A1 AU2003259971A1 (en) | 2004-03-11 |
| AU2003259971B2 true AU2003259971B2 (en) | 2009-03-05 |
Family
ID=31946810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003259971A Ceased AU2003259971B2 (en) | 2002-08-21 | 2003-08-20 | Compositions and methods for treating skin conditions |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7402323B2 (enExample) |
| EP (1) | EP1539105A2 (enExample) |
| JP (1) | JP2006500368A (enExample) |
| CN (1) | CN1678293A (enExample) |
| AU (1) | AU2003259971B2 (enExample) |
| CA (1) | CA2495870C (enExample) |
| MX (1) | MXPA05001954A (enExample) |
| WO (1) | WO2004017901A2 (enExample) |
| ZA (1) | ZA200501763B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8778369B2 (en) * | 2005-07-29 | 2014-07-15 | Delaval Holding Ab | Barrier film-forming compositions and methods of use |
| DE102006019293A1 (de) * | 2006-04-21 | 2007-10-25 | LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH | Pflaster, enthaltend ein Fentanyl Analogum |
| WO2008154141A2 (en) * | 2007-05-22 | 2008-12-18 | Prelief Inc. | Compositions and methods for preventing, minimizing and healing skin irritation and trauma |
| WO2009029692A1 (en) * | 2007-08-30 | 2009-03-05 | Prelief Inc. | Methods for improving healing of an oral lesion using a glycerophosphate salt |
| WO2009064412A1 (en) * | 2007-11-15 | 2009-05-22 | Prelief Inc. | Methods and compositions for wound healing |
| ITVR20080076A1 (it) * | 2008-06-30 | 2010-01-01 | Federico Visentini | Composizione per uso topico |
| US20100210600A1 (en) * | 2009-02-19 | 2010-08-19 | Prelief Inc. | Methods and Compositions for Treating Urogenital Disorders |
| EP2233128A1 (en) | 2009-03-25 | 2010-09-29 | Cognis IP Management GmbH | Cosmetic composition |
| CN105163740A (zh) | 2013-02-20 | 2015-12-16 | 普瑞丽芙有限公司 | 治疗和防治肠道损伤、紧密连接部功能障碍相关疾病的方法和组合物 |
| JP2014208597A (ja) * | 2013-04-16 | 2014-11-06 | オリザ油化株式会社 | 爪におけるセラミド含量増加剤 |
| CN104367513A (zh) * | 2014-11-17 | 2015-02-25 | 青岛厚科信息工程有限公司 | 一种纯天然女性皮肤护理液及其制备方法 |
| CN105125427A (zh) * | 2015-10-26 | 2015-12-09 | 北京化工大学 | 一种皮肤保湿修复凝胶及其制备方法 |
| JP2018188400A (ja) * | 2017-05-10 | 2018-11-29 | 英保 平野 | 褥瘡治療剤 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4743442A (en) * | 1983-08-02 | 1988-05-10 | Blendax-Werke R. Schneider Gmbh & Co. | Skin care composition |
| AU3834097A (en) * | 1996-10-07 | 1998-04-09 | La Roche Posay Laboratoire Pharmaceutique | W/O emulsion with a high electrolyte content, and its use in dermo-cosmetics, in particular for treating phenomena of irritation and/or of sensitive skin |
| US5972321A (en) * | 1998-06-30 | 1999-10-26 | Akpharma Inc. | Acid neutralization of skin |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2118566A (en) | 1935-08-29 | 1938-05-24 | Miles Gilbert De Wayne | Buffered cosmetic |
| US4197316A (en) | 1975-07-23 | 1980-04-08 | Scott Eugene J Van | Treatment of dry skin |
| US4363815A (en) | 1975-07-23 | 1982-12-14 | Yu Ruey J | Alpha hydroxyacids, alpha ketoacids and their use in treating skin conditions |
| US4021572A (en) | 1975-07-23 | 1977-05-03 | Scott Eugene J Van | Prophylactic and therapeutic treatment of acne vulgaris utilizing lactamides and quaternary ammonium lactates |
| US4380549A (en) | 1975-07-23 | 1983-04-19 | Scott Eugene J Van | Topical treatment of dry skin |
| JPS5833998A (ja) * | 1981-08-21 | 1983-02-28 | Hitachi Ltd | パルス幅変調インバ−タによる誘導電動機の制御方式 |
| US4588590A (en) | 1981-12-21 | 1986-05-13 | Jaye-Boern Laboratories, Inc. | Method of treating keratosis and compositions useful therefor |
| IT1153909B (it) | 1982-12-17 | 1987-01-21 | Sogimi Srl | Polimeri reattivi per la cura di affezioni cutanee |
| US4940666A (en) | 1983-07-15 | 1990-07-10 | University Patents, Inc. | Process and defined medium for growth of human epidermal keratinocyte cells |
| US4772591A (en) | 1985-09-25 | 1988-09-20 | Peritain, Ltd. | Method for accelerated wound healing |
| IT1213330B (it) | 1986-08-28 | 1989-12-20 | Rol Spa | Tensioattivi derivati da idrossiacidi bi- o tri-carbossilici. |
| FR2636339B1 (fr) | 1988-09-09 | 1992-07-17 | Auge Pier | Gel aqueux a base d'acide hyaluronique et d'acide desoxyribonucleique utilisable en cosmetique, et procede de preparation |
| US5084281A (en) | 1989-02-14 | 1992-01-28 | Dillon Richard S | Method and solution for treating tissue wounds |
| US5292655A (en) | 1990-01-29 | 1994-03-08 | Wille Jr John J | Method for the formation of a histologically-complete skin substitute |
| US5139771A (en) | 1990-04-16 | 1992-08-18 | Revlon, Inc. | Rinse away face masque |
| US5194261A (en) | 1990-11-27 | 1993-03-16 | Virgil Pichierri | Diaper rash treatment |
| US5602183A (en) | 1991-03-01 | 1997-02-11 | Warner-Lambert Company | Dermatological wound healing compositions and methods for preparing and using same |
| US5658956A (en) | 1991-03-01 | 1997-08-19 | Warner-Lambert Company | Bioadhesive-wound healing compositions and methods for preparing and using same |
| GB9210574D0 (en) | 1992-05-18 | 1992-07-01 | Ca Nat Research Council | Biotherapeutic cell-coated microspheres for wound/burn and prothesis implant applications |
| US6287548B1 (en) | 1993-11-22 | 2001-09-11 | Bio.Life International Ag | Treatment of acne, seborrheic dermatitis and other skin diseases with salt solution containing NACL |
| FR2725901B1 (fr) * | 1994-10-25 | 1997-06-27 | Thorel Jean Noel | Utilisation du calcium en cosmetologie dans le traitement local des phenomenes irritatifs |
| EP0741559B1 (en) | 1994-11-03 | 2004-09-29 | Estee Lauder Inc. | Sprayable compositions containing dispersed powders and methods for using the same |
| DE19509354A1 (de) | 1994-12-08 | 1996-06-13 | Klett Loch Lore M | Kombinationspräparat zur Förderung des Haarwachstums und ggf. des Haut- und Nagelwachstums sowie zur Verhinderung bzw. zur Beseitigung von Haarausfall |
| US5716625A (en) | 1994-12-21 | 1998-02-10 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
| US5660859A (en) | 1994-12-29 | 1997-08-26 | Mcneil-Ppc, Inc. | Gelling agent for polyethylene glycol |
| US5643586A (en) | 1995-04-27 | 1997-07-01 | Perricone; Nicholas V. | Topical compositions and methods for treatment of skin damage and aging using catecholamines and related compounds |
| US5922335A (en) | 1995-05-15 | 1999-07-13 | Avon Products, Inc. | Uses for ascorbyl-phosphoryl-cholesterol in topical compositions |
| US5866147A (en) | 1995-05-15 | 1999-02-02 | Avon Products, Inc. | Ascorbyl-phosphoryl-cholesterol |
| US5958436A (en) | 1995-12-21 | 1999-09-28 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
| US5593682A (en) | 1995-12-29 | 1997-01-14 | Eastman Chemical Company | Skin treating composition |
| FR2746007B1 (fr) | 1996-03-12 | 1998-04-24 | Composition gelifiee stable a forte teneur en electrolyte et son utilisation dans les domaines cosmetique, pharmaceutique et/ou dermatologique | |
| FR2750863B1 (fr) | 1996-07-10 | 1998-09-25 | Oreal | Utilisation d'un polyholoside dans une composition destinee a favoriser la desquamation de la peau, et composition la comprenant |
| FR2754452B1 (fr) | 1996-10-11 | 2003-02-14 | Oreal | Emulsion h/e a forte teneur en electrolytes et leur utilisation en dermo-cosmetique, notamment pour traiter les phenomenes d'irritation et/ou de peaux sensibles |
| US5776473A (en) | 1997-01-17 | 1998-07-07 | Warner-Lambert Company | Razor comfort strip with alpha-hydroxy acid additive |
| US6168798B1 (en) | 1997-02-03 | 2001-01-02 | Bristol-Myers Squibb Company | Non-irritating composition for treating acne and other skin conditions |
| US6063406A (en) | 1997-04-18 | 2000-05-16 | Chemcraft, Inc. | Skin care compositions |
| JPH11100320A (ja) * | 1997-09-29 | 1999-04-13 | Risuburan:Kk | 皮膚外用剤 |
| JP3634610B2 (ja) * | 1998-01-27 | 2005-03-30 | 富士通株式会社 | 自動コールシステム |
| US5922359A (en) * | 1998-02-17 | 1999-07-13 | Youssefyeh; Rena T. | Skin treatment compositions comprising unoxidized nerve tissue |
| US6080425A (en) | 1998-05-26 | 2000-06-27 | Topgene, Inc. | Boron compounds and complexes as skin-rejuvenating agents |
| FR2783706B1 (fr) | 1998-09-25 | 2002-06-07 | Oreal | Composition aqueuse gelifiee stable a forte teneur en electrolyte |
| FR2785535B1 (fr) | 1998-11-06 | 2002-06-14 | Oreal | Poudre cosmetique et/ou dermatologique, son procede de preparation et ses utilisations |
| EP1154804B1 (en) | 1999-02-26 | 2008-02-20 | Johnson & Johnson Consumer Companies, Inc. | Bioadhesive antibacterial wound healing composition |
| US6184247B1 (en) | 1999-05-21 | 2001-02-06 | Amway Corporation | Method of increasing cell renewal rate |
| AU772096B2 (en) * | 2000-03-14 | 2004-04-08 | Sumika Enviro-Science Co., Ltd. | Method for denaturing allergens |
-
2003
- 2003-08-12 US US10/639,213 patent/US7402323B2/en not_active Expired - Fee Related
- 2003-08-20 JP JP2004529780A patent/JP2006500368A/ja active Pending
- 2003-08-20 MX MXPA05001954A patent/MXPA05001954A/es active IP Right Grant
- 2003-08-20 CN CNA038197685A patent/CN1678293A/zh active Pending
- 2003-08-20 EP EP03793221A patent/EP1539105A2/en not_active Withdrawn
- 2003-08-20 WO PCT/US2003/026194 patent/WO2004017901A2/en not_active Ceased
- 2003-08-20 CA CA2495870A patent/CA2495870C/en not_active Expired - Fee Related
- 2003-08-20 AU AU2003259971A patent/AU2003259971B2/en not_active Ceased
-
2005
- 2005-03-01 ZA ZA200501763A patent/ZA200501763B/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4743442A (en) * | 1983-08-02 | 1988-05-10 | Blendax-Werke R. Schneider Gmbh & Co. | Skin care composition |
| AU3834097A (en) * | 1996-10-07 | 1998-04-09 | La Roche Posay Laboratoire Pharmaceutique | W/O emulsion with a high electrolyte content, and its use in dermo-cosmetics, in particular for treating phenomena of irritation and/or of sensitive skin |
| US5972321A (en) * | 1998-06-30 | 1999-10-26 | Akpharma Inc. | Acid neutralization of skin |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003259971A1 (en) | 2004-03-11 |
| CA2495870C (en) | 2011-11-22 |
| WO2004017901A3 (en) | 2004-09-02 |
| MXPA05001954A (es) | 2005-04-28 |
| CN1678293A (zh) | 2005-10-05 |
| US7402323B2 (en) | 2008-07-22 |
| US20040037766A1 (en) | 2004-02-26 |
| JP2006500368A (ja) | 2006-01-05 |
| WO2004017901A2 (en) | 2004-03-04 |
| EP1539105A2 (en) | 2005-06-15 |
| CA2495870A1 (en) | 2004-03-04 |
| ZA200501763B (en) | 2006-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9211244B2 (en) | Method for anti-skin aging using caffeamide derivative | |
| JP3457467B2 (ja) | 皮膚への局所適用組成物 | |
| US6335368B1 (en) | Use of alverine for reducing wrinkles | |
| AU2003259971B2 (en) | Compositions and methods for treating skin conditions | |
| WO2002015860A1 (en) | Topical antioxidant having vitamin c and method of combination with topical agent by user | |
| KR20150105307A (ko) | 비천연 흡습성 아미노산을 함유하는 피부 조성물 | |
| JP2001139475A (ja) | エスシンとデキストラン硫酸の組合せ及びそれらの用途 | |
| JP2005509660A (ja) | エタノールアミン誘導体および有機金属塩を含んでなる組成物 | |
| JPH0217122A (ja) | 皮膚疾患の処置 | |
| US6267948B1 (en) | Dermatological formulations and methods | |
| US20060120980A1 (en) | Novel dermatological composition using bio-activating organocatalysts | |
| US20070190175A1 (en) | Skin care composition for dermatological disorders | |
| KR100955312B1 (ko) | 피토스핑고신의 체중감소제로서의 화장품적 용도 및피토스핑고신을 함유하는 화장품 조성물 | |
| KR101503158B1 (ko) | 피부 주름 개선 및 탄력 증진용 화장료 조성물 | |
| EP0949919B1 (en) | A process for stabilizing levogyre ascorbic acid (laa) and stable laa compositions | |
| KR101446706B1 (ko) | Ｆｇｆ를 포함하는 피부 재생용 조성물 | |
| US20140234433A1 (en) | Topical Composition for Stimulating Epidermis and Dermis Layers of the Skin | |
| DK1272157T3 (en) | Topical micronutrient delivery system and applications thereof | |
| JPH1160481A (ja) | 皮膚外用剤のイオン導入液 | |
| US20050276766A1 (en) | Methods and compositions for increasing skin remodeling | |
| RU2825001C1 (ru) | Средство для лечения ожогов | |
| KR20250114272A (ko) | 튜불린 저해제를 포함하는 병용요법을 이용한 피부 질환 예방 또는 치료용 조성물 | |
| WO2023209655A1 (en) | Skin cell energy booster composition | |
| US6685965B1 (en) | Process for stabilizing levogyre ascorbic acid (laa), a stable aqueous laa composition, a process for preparing a stable topical solution, an emulsion, a vitamin product, and a method for cosmetic, pharmaceutical or nutritional treatment | |
| KR20070006626A (ko) | 피부의 국부조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |